Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.

Chimeric antigen receptor-modified T Cells inhibit the growth and metastases of established tissue factor-positive tumors in NOG mice.
复制标题

DOI:
10.18632/oncotarget.14367
复制
发表时间:
2017-02-07
期刊:
影响因子:
--
通讯作者:
Zheng J
Zheng J
中科院分区:
其他
文献类型:
--
作者:
Zhang Q;Wang H;Li H;Xu J;Tian K;Yang J;Lu Z;Zheng J

文献摘要

参考文献

被引文献

相似文献

嵌合抗原受体(CAR)修饰的T细胞(CAR T)是癌症患者的有希望的治疗选择。这种方法需要鉴定在实体瘤中表达的肿瘤特异性抗原靶标。我们开发了一种新的第三代CAR,针对组织因子(TF),一种在某些类型的肺癌,黑色素瘤和其他癌症中过表达的表面分子。首先,我们通过免疫组织化学方法证明了TF在非小细胞肺癌(NSCLC)的鳞状细胞癌和腺癌以及黑色素瘤中过表达。在TF阳性癌细胞的存在下,CAR修饰的T细胞(TF-CAR T)被高度活化,并在体外显示出对TF阳性癌细胞的特异性细胞毒性。在建立的s.c.在异种移植和肺转移模型中,TF-CAR T细胞可以显著抑制s.c. TF阳性癌细胞的异种移植和转移。此外,TF-CAR T细胞在体内的安全性评估显示,该治疗在小鼠中没有引起明显的毒性。总之,这些发现表明TF-CAR T细胞可能是治疗TF阳性癌症患者的新型潜在治疗剂。
Chimeric antigen receptor (CAR)-modified T cell (CAR T) is a promising therapeutic option for patients with cancer. Such an approach requires the identification of tumor-specific antigen targets that are expressed in solid tumors. We developed a new third-generation CAR directed against tissue factor (TF), a surface molecule overexpressed in some types of lung cancer, melanoma and other cancers. First, we demonstrated by immunohistochemistry that TF was overexpressed in squamous cell carcinoma and adenocarcinoma of non-small cell lung cancer (NSCLC) and melanoma using a human tissue microarray. In the presence of TF-positive cancer cells, the CAR-modified T cells (TF-CAR T) were highly activated and showed specific cytotoxicity to TF-positive cancer cells in vitro. In established s.c. xenograft and lung metastasis models, TF-CAR T cells could significantly suppress the growth of s.c. xenograft and metastasis of TF-positive cancer cells. Additionally, the safety evaluation of TF-CAR T cells in vivo showed that the treatment did not cause obvious toxicity in mice. Taken together, these findings indicate that TF-CAR T cells might be a novel potential therapeutic agent for the treatment of patients with TF-positive cancers.
DOI: 10.3892/ol.2013.1437
发表时间: 2013-09
期刊: Oncology letters
影响因子: 2.9
作者:
Zhang Q;Liu X;Li C;Liao D;Ouyang Z;Zheng J;Song X
通讯作者: Song X